Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Import Substitution in Russia

Tuesday, March 31, 2015

RNC Pharma sums up the first wave of the analytical project “Monitoring of Import Substitution in Russia”. This is a detailed analysis of the intensity of import substitution in the most capital-intensive sectors, i.e. evaluation of the activity and depth of the localization of foreign pharmaceutical drugs in the Russian market.

The first wave of the project analyzed the 57 pharmaceutical drugs of strategic importance, the drugs on the 2015 VED list, and the drugs on the 2015 list of high-cost nosologies. Apart from those already available, 72 Russian alternatives to 33 INNs out of the 57 strategically important pharmaceutical drugs will appear in the Russian pharmaceutical market in 2015–2017, which confirms that import substitution is working. The role of the localization is relatively small, though, as foreign companies produce 22 out of the 57 strategically important drugs at Russian factories, with the full-cycle production of only 7 drugs.

As for the 2015 VED list, the situation for foreign companies is even more serious. At Russian factories, foreign companies produce only 69 drugs out of more than 600 INNs, with the full-cycle production of only 24 drugs.

Please download the Powerpoint presentation and an example of the interpretation of the results here. You can also download the demo of the report here.

If you would like the full report, please contact